<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00362219</url>
  </required_header>
  <id_info>
    <org_study_id>RMC-2468.CTIL</org_study_id>
    <nct_id>NCT00362219</nct_id>
  </id_info>
  <brief_title>Topical Morphine for Analgesia in Patients With Skin Grafts</brief_title>
  <official_title>Topical Morphine for Analgesia in Patients With Skin Grafts</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rambam Health Care Campus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rambam Health Care Campus</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The management of pain endured by patients after skin grafting is complex. Pain is the single&#xD;
      most distressing symptom but as it is difficult to manage, it is often under-treated. These&#xD;
      patients may experience pain from two types of wound: the original injury and from&#xD;
      &quot;skin-donor&quot; sites, areas of healthy skin from which skin is surgically removed and used to&#xD;
      cover the original injury. As the section of skin which is removed is standardized, the wound&#xD;
      created at the donor site is uniform and so provides a model of an acute wound.&#xD;
&#xD;
      Opioids (such as morphine) are the backbone of treating the moderate to severe pain&#xD;
      experienced by any patient. But due to their potentially severe side effects and that some&#xD;
      patients do not experience sufficient relief from the treatment, optimal treatment schedules&#xD;
      are still being sought after.&#xD;
&#xD;
      Topically applied morphine has provided effective and safe analgesia in several clinical&#xD;
      models. We, therefore, wish to apply this treatment modality onto skin-graft donor wounds. If&#xD;
      found to be effective this could be an appealing non-invasive method to treat the pain of&#xD;
      this type of wound.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Administration of morphine into the knee joint is the best-studied clinical procedure&#xD;
      documenting the use of topically-applied opioids. When 1-5 mg morphine were injected into the&#xD;
      knee joint, patients experienced pain relief for up to 24 hours, whereas similar doses given&#xD;
      systemically (i.e. intravenously) were effective for 2-4 hours. Furthermore, the analgesic&#xD;
      effect was reversed when the opioid antagonist naloxone was injected into the knee joint.&#xD;
      Both these findings indicate that the effect is mediated by local opioid receptors in the&#xD;
      knee joint.&#xD;
&#xD;
      Peripheral analgesic effects of opioids are not detectable in normal tissue but appear&#xD;
      minutes to hours after initiation of inflammation. This suggests that opioid receptors are&#xD;
      already present in the peripheral nerve terminals but under normal conditions they are not&#xD;
      functional.&#xD;
&#xD;
      Research on application of opioids to skin wounds is very sparse and has primarily been&#xD;
      performed in palliative care patients. These reports demonstrate that topical opioid gel&#xD;
      (morphine or diamorphine) provided rapid and effective relief. In some patients pain subsided&#xD;
      within 20 minutes after application with a long-lasting (7-8 hours) effect. Fundamental&#xD;
      aspects regarding topical application of opioids onto skin wounds are still lacking. For&#xD;
      example, issues such as optimal dose and dose-effect relationships have not been&#xD;
      investigated. We hope to determine these in this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain score in first 24 hours</measure>
    <time_frame>24 hours after application of the medication</time_frame>
    <description>Sum of the differences in pain scores between the skin-donor site vs. original injury site taken over a 24 hour period after application of the medication.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Score</measure>
    <time_frame>24 hours after surgery</time_frame>
    <description>Pain score at skin-donor site using an abbreviated form of the McGill Pain Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time course of analgesia for each drug concentration</measure>
    <time_frame>First 24 hours after surgery</time_frame>
    <description>Time course of analgesia for each drug concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects</measure>
    <time_frame>First 24 hours after surgery</time_frame>
    <description>Presence and severity of side effects: (a) central (nausea, vomiting, sedation, purities) and (b) local (burning, tingling, wheal, flare)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Supplementary analgesic medications</measure>
    <time_frame>First 24 hours after surgery</time_frame>
    <description>Concurrent, supplementary, &quot;rescue&quot;, analgesic medication (i.v.or oral morphine), given during the first 24 hours post operatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analgesic medicine from 2nd post-operative day until dressings are removed.</measure>
    <time_frame>Day 2 post-surgery through 12th post-op day on average</time_frame>
    <description>Analgesic medication (type and dose), given from the second post-operative day until dressings are removed for the first time (= the 12th post-operataive day, on average).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain score collection</measure>
    <time_frame>Twice daily from day 2 post-op until day 8 post-op</time_frame>
    <description>Pain scores at donor and original injury, twice daily, from the second post-operative day until dressings are removed for the first time - up until 8th post-op day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wound assessment</measure>
    <time_frame>Average day 12 post-operative</time_frame>
    <description>Assessment of the wound once the dressings are removed</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Skin Transplantation</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Gel with no active ingredient</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Morphine .25 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gel with 0.25 mg morphine per 100cm2 square of wound</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Morphine - .75 mg.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gel with 0.75 mg morphine per 100cm2 square of wound.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Morphine 1.25 mg.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gel with 1.25 mg morphine per 100cm2 square of wound.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Gel with no active ingredient.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine - .25 mg</intervention_name>
    <description>gel with 0.25 mg morphine per 100cm2 square of wound.</description>
    <arm_group_label>Morphine .25 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine</intervention_name>
    <description>Gel with 0.75 mg morphine per 100cm2 square of wound.</description>
    <arm_group_label>Morphine - .75 mg.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine</intervention_name>
    <description>Gel with 1.25 mg morphine per 100cm2 square of wound.</description>
    <arm_group_label>Morphine 1.25 mg.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients undergoing skin-grafting&#xD;
&#xD;
          -  American Society of Anesthesiologists (ASA) classification I-II&#xD;
&#xD;
          -  Written consent&#xD;
&#xD;
          -  Either sex&#xD;
&#xD;
          -  Able to self-asses and report their pain level&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Alcohol abuse or addiction - current&#xD;
&#xD;
          -  Opioids and benzodiazepines abuse - life time&#xD;
&#xD;
          -  Known hypersensitivity to morphine&#xD;
&#xD;
          -  Major renal or hepatic dysfunction&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Sleep-apnoea-syndrome&#xD;
&#xD;
          -  Diabetes&#xD;
&#xD;
          -  Participation in other clinical studies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yehuda Ullman, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rambam Health Care Campus</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yehuda Ullman, M.D.</last_name>
    <phone>+972-4-8542974</phone>
    <email>y_ullmann@rambam.health.gov.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Plastic Surgery, Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
    <investigator>
      <last_name>Yehuda Ullman, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Krajnik M, Zylicz Z, Finlay I, Luczak J, van Sorge AA. Potential uses of topical opioids in palliative care--report of 6 cases. Pain. 1999 Mar;80(1-2):121-5.</citation>
    <PMID>10204724</PMID>
  </reference>
  <reference>
    <citation>Stein C, Comisel K, Haimerl E, Yassouridis A, Lehrberger K, Herz A, Peter K. Analgesic effect of intraarticular morphine after arthroscopic knee surgery. N Engl J Med. 1991 Oct 17;325(16):1123-6.</citation>
    <PMID>1653901</PMID>
  </reference>
  <reference>
    <citation>Porzio G, Aielli F, Verna L, Cannita K, Marchetti P, Ficorella C. Topical morphine in the treatment of painful ulcers. J Pain Symptom Manage. 2005 Oct;30(4):304-5.</citation>
    <PMID>16256893</PMID>
  </reference>
  <reference>
    <citation>Ribeiro MD, Joel SP, Zeppetella G. The bioavailability of morphine applied topically to cutaneous ulcers. J Pain Symptom Manage. 2004 May;27(5):434-9.</citation>
    <PMID>15120772</PMID>
  </reference>
  <reference>
    <citation>Stein A, Yassouridis A, Szopko C, Helmke K, Stein C. Intraarticular morphine versus dexamethasone in chronic arthritis. Pain. 1999 Dec;83(3):525-532. doi: 10.1016/S0304-3959(99)00156-6.</citation>
    <PMID>10568861</PMID>
  </reference>
  <reference>
    <citation>Zeppetella G, Ribeiro MD. Morphine in intrasite gel applied topically to painful ulcers. J Pain Symptom Manage. 2005 Feb;29(2):118-9.</citation>
    <PMID>15733803</PMID>
  </reference>
  <reference>
    <citation>Stein C, Schäfer M, Machelska H. Attacking pain at its source: new perspectives on opioids. Nat Med. 2003 Aug;9(8):1003-8. Review.</citation>
    <PMID>12894165</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>August 8, 2006</study_first_submitted>
  <study_first_submitted_qc>August 8, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2006</study_first_posted>
  <last_update_submitted>March 10, 2021</last_update_submitted>
  <last_update_submitted_qc>March 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rambam Health Care Campus</investigator_affiliation>
    <investigator_full_name>Yehuda Ullmann MD</investigator_full_name>
    <investigator_title>Head, Plastic Surgery Department</investigator_title>
  </responsible_party>
  <keyword>topical</keyword>
  <keyword>morphine</keyword>
  <keyword>pain</keyword>
  <keyword>skin-wound</keyword>
  <keyword>skin-graft</keyword>
  <keyword>peripheral analgesia</keyword>
  <keyword>burn</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

